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Background: Pompe disease is a rare metabolic myopathy for which disease-specific enzyme replacement therapy
(ERT) has been available since 2006. ERT has shown efficacy concerning muscle strength and pulmonary function in
adult patients. However, no data on the effect of ERT on the survival of adult patients are currently available. The
aim of this study was to assess the effect of ERT on survival in adult patients with Pompe disease.
Methods: Data were collected as part of an international observational study conducted between 2002 and 2011,
in which patients were followed on an annual basis. Time-dependent Cox’s proportional hazards models were used
for univariable and multivariable analyses.
Results: Overall, 283 adult patients with a median age of 48 years (range, 19 to 81 years) were included in the
study. Seventy-two percent of patients started ERT at some time during follow-up, and 28% never received ERT.
During follow-up (median, 6 years; range, 0.04 to 9 years), 46 patients died, 28 (61%) of whom had never received
ERT. After adjustment for age, sex, country of residence, and disease severity (based on wheelchair and ventilator
use), ERT was positively associated with survival (hazard ratio, 0.41; 95% CI, 0.19 to 0.87).
Conclusion: This prospective study was the first to demonstrate the positive effect of ERT on survival in adults with
Pompe disease. Given the relatively recent registration of ERT for Pompe disease, these findings further support its
beneficial impact in adult patients.
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Pompe disease (glycogen storage disease type II, acid
maltase deficiency) is a rare metabolic myopathy caused
by a deficiency of lysosomal acid α-glucosidase (GAA),
resulting in the intralysosomal accumulation of glycogen.
Pompe disease is characterized by a progressive loss of
muscle strength and respiratory function and is inheri-
ted in an autosomal recessive manner [1]. Historically,* Correspondence: a.vanderploeg@erasmusmc.nl
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reproduction in any medium, provided the orsupportive care has been the mainstay of treatment. Fol-
lowing decades of research, enzyme replacement therapy
(ERT) for Pompe disease was approved in Europe and
the United States in 2006, prompting a new era in the
treatment of this disease. This was the first disease-
specific treatment for an inherited muscular disorder, [2]
consisting of the intravenous administration of recom-
binant human GAA (alglucosidase alfa) [3].
The therapeutic efficacy of alglucosidase alfa was first
demonstrated in classic infantile Pompe disease [3,4].
Patients with classic infantile Pompe disease present
with symptoms shortly after birth and develop signifi-
cant, progressive hypertrophic cardiomyopathy and lossl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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untreated [5]. Cardiorespiratory failure is the primary
cause of mortality, typically occurring within the first
year of life [5]. With the introduction of ERT, survival in
patients with classic infantile Pompe disease has in-
creased significantly; [5] the oldest infants treated with
ERT are now 14 years of age [4,6].
The rapid decline in classic infantile Pompe disease is
explained by the complete lack of GAA activity [1]. How-
ever, the majority of patients with Pompe disease express
some residual GAA activity, leading to a spectrum of dis-
ease presentations [7]. In adults, the disease progresses
more slowly, with loss of ambulation and wheelchair and
respirator dependency developing in later stages of the
disease at varying ages [8]. Their primary cause of death is
respiratory failure [1,7].
Trials of ERT in adults were initiated much later than
those in infants. The first and only placebo-controlled ran-
domized trial started at the end of 2005 and included 90
patients. Over a period of 78 weeks, treatment with
alglucosidase alfa resulted in an improved walking dis-
tance on the six-minute walk test and stabilization of pul-
monary function, meeting both primary endpoints of the
trial [9]. Since 2006, more adult patients are gradually be-
ing treated [10-15], but no studies to date have assessed
the impact of ERT on survival in adults.
As an ultra-orphan drug, alglucosidase alfa is an expen-
sive treatment; in several countries around the world, its
high cost and lifelong administration have led to a debate
on its reimbursement in adults. Survival is a key param-
eter in this discussion. Our centre has systematically col-
lected data on patients with Pompe disease since 2002,
before the approval of ERT. This activity has provided a
unique set of long-term survey-based data allowing the
evaluation of a large international patient population, both
treated and untreated. To date, this database has the lon-
gest consistent follow-up providing information on pa-
tients with Pompe disease prior to and following ERT
initiation. Findings from this survey recently revealed that
untreated adults with Pompe disease have higher mortality
than the general population [16]. Age, wheelchair and
ventilator dependency, and level of handicap appeared to
be the main indicators of lower life expectancy [16].
The aim of the current study was to use data collected
from the same patient survey to explore the potential ef-
fect of ERT on survival in adults with Pompe disease.
We report here the results of this prospective, inter-
national observational study.
Methods
The International Pompe Association/Erasmus MC Pompe
Survey
The International Pompe Association (IPA)/Erasmus MC
Pompe Survey, an ongoing international observationalfollow-up study on the clinical course of patients with
Pompe disease, has continually enrolled patients since May
2002. The design of this prospective study was described
elsewhere [17,18]. Patients were recruited through patient
organizations affiliated with the IPA from Australia,
Canada, Germany, the Netherlands, the United Kingdom,
the United States, and a small number of patients from
other countries. Dutch patients included in the analyses
participated either directly through Erasmus MC (the
designated centre for all known patients with Pompe
disease in the Netherlands) or through the Dutch
patient organization. Enrolment was independent of
the stage of disease and the age of disease onset.
The IPA/Erasmus MC Pompe Survey covers the entire
spectrum of the disease and is representative of the adult
Pompe population [19].
Information was collected through annual question-
naires, which asked patients about their medical history,
current disease status, use of care, and quality of life. For
Dutch patients, additional data were obtained during
regular clinical evaluations at Erasmus MC, producing
more frequent follow-up measurements than for other
patients. The date of the last completed questionnaire
before September 2011 was considered as the date of
last follow-up, or - for the Dutch group - the date of the
last visit if this came last. When questionnaires were not
returned it was investigated whether the patient had
died. The date of death was either reported, or estimated
to be halfway between the date of completion of the last
questionnaire and the date at which the next question-
naire should have been completed.
All research protocols were approved by the Medical
Ethics Committee of Erasmus MC and/or the Central
Committee on Research Involving Human Subjects.
Written informed consent was obtained from all patients.
The current study included only patients 18 years of
age or older at study entry and used data collected until
September 2011. At that time, the database included in-
formation on 369 participants 18 years of age or older at
enrolment. Patients were excluded from the analysis if
only baseline data were available (n=71), if they had
started receiving ERT before study enrolment (n=13), or
if relevant baseline data were missing (n=2).
Statistical analysis
Data describing the patients’ characteristics are pre-
sented as medians and ranges. Patient characteristics
were compared using the Mann–Whitney test or the χ2
test. Survival time was assessed from the date of study
entry until the date of last follow-up or until death. The
association between overall survival of adult patients
and treatment with ERT was estimated using time-
dependent Cox proportional hazard regression models,
both for univariable as well as multivariable analyses.
Table 1 Patient characteristics and follow-up*
Characteristics n = 283
Female, n (%) 149 (53)
Median age at study entry, years (range) 48 (19–81)
Median age at diagnosis, years (range) 38 (1–72)
Median disease duration at study entry, years (range) 9 (0–32)
Country of residence, n (%)
Netherlands 109 (39)
United Kingdom 23 (8)
United States 71 (25)
Germany 48 (17)
Other† 32 (11)
Disease severity at study entry, n (%)
No wheelchair use or respiratory support‡ 134 (47)
Wheelchair use 37 (13)
Use of respiratory support 42 (15)
Both wheelchair use and respiratory support 70 (25)
Median follow-up time, years (range) 6 (0.04-9)
ERT during the course of the study, n (%) 204 (72)
Median ERT duration, years (range) 4 (0.2-8)
Median age at start of ERT, years (range) 51 (24–76)
Died during follow-up, n (%) 46 (16)
Median age at death, years (range) 59 (23–86)
* Continuous variables are expressed as median (range). Categorical variables
are expressed as n (%). ERT denotes enzyme replacement therapy.
† Including patients from Australia and Canada.
‡ Respiratory support includes partial and full-time invasive and non-invasive
respiratory support.
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priori: age, sex, disease severity (based on wheelchair
and ventilator use), and country of residence. The results
are presented as hazard ratios (HRs) with 95% confi-
dence intervals (CIs).
Two models were generated to describe the relation-
ship between ERT and overall survival in adult patients
with Pompe disease. In both models, ERT was included
as a time-dependent covariate that took the value 0 be-
fore the start of treatment and switched to 1 at the start
of treatment. As long as patients were not receiving
ERT, they contributed to the untreated group and acted
as controls for the treated patients during the treatment
period. In the primary model (model 1a), in addition to
ERT, age categories and disease severity were also mod-
elled as time-dependent covariates and hence were
updated at the start of ERT. An intent-to-treat approach
was adopted in which patients who discontinued treat-
ment were considered to have remained in the treatment
group until the end of follow-up. The sensitivity of these
analyses to including age and severity as time-dependent
covariates was investigated using a second model with
ERT as a time-dependent variable only (model 2a). Fur-
ther to the intent-to-treat approach, the primary and
secondary analyses were also conducted to account for
the actual treatment duration. In these models, all pa-
tients who discontinued treatment were censored at the
time of discontinuation (models 1b and 2b). The validity
of the proportional hazards assumption was assessed by
examining plots of the cumulative hazard function on a
linear and logarithmic scale, stratified by categories of
the covariates. Proportionality was assumed if the curves
were parallel.
Statistical tests were conducted using SPSS for Win-
dows (version 17; SPSS Inc., Chicago, IL) and SAS (ver-
sion 9·2; SAS Institute Inc., Cary, NC). A P-value ≤0.05
was considered statistically significant.
Results
Patient characteristics
Overall, 283 adult patients with Pompe disease (77% of
those enrolled) were eligible for analysis. The baseline
characteristics of these patients are shown in Table 1.
Seventy-two percent of patients started ERT at some
time during follow-up, and 28% never received ERT.
The median age of the patients at study entry was 48
years (range, 19 to 81 years), with a median disease dur-
ation of 9 years (range, 0 to 32 years). Fifty-three percent
of the patients were women.
Table 2 shows the characteristics of the ERT and the
non-ERT groups at the start of ERT and at study entry.
For patients who received ERT during follow-up, the
median age at the start of ERT was comparable to the
median age at study entry of patients who never receivedERT. Differences in sex, age at diagnosis, disease dur-
ation, and disease severity (based on use of wheelchair
and respiratory support) between treated patients at the
start of ERT and untreated patients at enrolment were
not significant, whereas country of residence differed
with borderline statistical significance.
During the 1676 person-years of follow-up (median,
6 years; range, 0.04 to 9 years), for 46 patients a death
confirmation was received from the patient organization,
the family or the treating physician. Twenty-eight (61%) of
these patients were in the non-ERT group. The median
age at death was 59 years (range, 23 to 86 years). Com-
pared with the total patient population, the deceased pa-
tients were more severely affected by Pompe disease at
study entry. Thirty-seven of the 46 deceased patients
(80%) used either a wheelchair or a ventilator or both at
study entry compared with 53% of the overall patient
population. Causes of death in 21 of the 46 cases were
(n=16) or could be (n=5) related to Pompe disease (e.g.,
respiratory insufficiency). In the remaining 25 cases, the
cause of death was either unknown (n=20) or not related
to Pompe disease (n=5). Of the 28 patients who died
Table 2 Patient characteristics for the ERT group at study entry or start of ERT and for untreated patients at study
entry*
ERT group (n = 204) Non-ERT group (n = 79) P Value†
Characteristics At study entry At start of ERT At study entry
Female, n (%) 104 (51) 104 (51) 45 (57) 0.37
Median age at study entry/start of ERT, years (range) 47 (19–73) 51 (24–76) 51 (20–81) 0.48
Median age at diagnosis, years (range) 38 (1–72) 38 (1–72) 42 (2–67) 0.45
Median disease duration at study entry/start of ERT, years (range) 7 (0–31) 11 (0.2-33) 12 (0–32) 0.75
Country of residence, n (%) 0.05
Netherlands 86 (42) 86 (42) 23 (29)
United Kingdom 18 (9) 18 (9) 5 (6)
United States 44 (22) 44 (22) 27 (34)
Germany 37 (18) 37 (18) 11 (14)
Other‡ 19 (9) 19 (9) 13 (17)
Disease severity at study entry/start of ERT, n (%) 0.45
No wheelchair use or respiratory support§ 99 (49) 70 (34) 35 (44)
Wheelchair use 26 (13) 37(18) 11 (14)
Use of respiratory support 31(15) 29 (14) 11 (14)
Both wheelchair use and respiratory support 48 (24) 68 (33) 22 (28)
Median follow-up time from study entry/start of ERT, years (range) 7 (1–9) 4 (0.2-8) 4 (0.04-9) 0.05
Died during follow-up, n (%) 18 (9) 18 (9) 28 (35) <0.001
* Continuous variables are expressed as median (range). Categorical variables are expressed as n (%). ERT denotes enzyme replacement therapy.
† P value for differences between ever-treated patients at the start of ERT and never-treated patients (at study entry) as assessed with a Mann–Whitney test or the
χ2 test.
‡ Including patients from Australia and Canada.
§ Respiratory support includes partial and full-time invasive and non-invasive respiratory support.
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year that ERT obtained approval (2006), and 9 died later.
Nineteen of the 204 patients who received ERT
stopped treatment during follow-up. The median treat-
ment duration in these patients was 1.4 years (range, 0.2
to 4.7 years), and the median time after stopping treat-
ment until the end of follow-up was 1.2 years (range,
0.05 to 4.0 years). Reasons for discontinuation were re-
lated to allergic type reactions/adverse events (n = 10),
lack of treatment effect (n = 4), pregnancy (n = 2), and
unknown (n = 3). Four of the patients who stopped
treatment died, including 3 who had received ERT for
less than 1.5 years. Of these 4 patients, 1 died 6 weeks
after stopping treatment, and the other 3 patients died
between 1 and 2.5 years after stopping treatment.
Association between Ert and survival
Table 3 summarizes the results from the primary multi-
variable Cox proportional hazard regression model
(model 1a). ERT was shown to be positively associated
with survival (HR, 0.46; 95% CI, 0.22 to 0.95) in the
univariable analysis. After adjustment for age, sex, coun-
try of residence, and disease severity, the HR for ERT
was 0.41 (95% CI, 0.19 to 0.87). The model using only
ERT as a time-dependent covariate (model 2a) producedan HR of 0.51 (95% CI, 0.24 to 1.10). The analyses in
which the patients who discontinued treatment were in-
cluded until discontinuation resulted in HRs of 0.33
(95% CI, 0.15 to 0.73) and 0.42 (95% CI, 0.19 to 0.93) for
models 1b and 2b, respectively. The Forest plot in
Figure 1 illustrates the HRs and 95% CIs of all models.
Discussion
This is the first study to show the beneficial effects of
ERT on the survival of adult patients with Pompe dis-
ease, a clinically meaningful finding especially given the
slowly progressive disease course and relatively short
treatment period. ERT in Pompe disease was initially ap-
proved for all patients in the United States and Europe
on the basis of the prolonged survival of severely af-
fected infants with classic Pompe disease and later by
the significant gain in walking distance and stabilized
pulmonary function in adult patients [8,9,20].
We observed the significant effect of ERT on survival
as part of an international observational study that pro-
vided access to data from 283 adult patients with Pompe
disease. Because most adult patients with Pompe disease
eventually die of respiratory failure [1,7], the beneficial
effect of ERT on survival is likely to be related to its
positive effect on pulmonary function. The hazard ratio
Table 3 Risk of death for 283 adults with Pompe disease applying time-dependent cox regression*
Model 1a†
Time-dependent cox regression model HR 95% CI P Value
ERT‡ 0.41 0.19 to 0.87 0.02
Age (in quartiles) 0.14
<37 years (ref) 1
37-48 years 1.26 0.38 to 4.12 0.71
48-57 years 1.42 0.44 to 4.61 0.56
≥57 years 2.57 0.86 to 7.72 0.09
Sex 1.01 0.55 to 1.87 0.98
Disease severity 0.001
No wheelchair use or respiratory support ‡ 1
Wheelchair use 2.87 0.98 to 8.36 0.05
Use of respiratory support 2.05 0.62 to 6.77 0.24
Both wheelchair use and respiratory support 5.32 2.25 to 12.56 <0.001
Country of residence 0.13
Netherlands (ref) 1
United Kingdom 1.35 0.46 to 3.95 0.58
United States 2.14 1.01 to 4.55 0.05
Germany 0.62 0.19 to 1.95 0.41
Other§ 1.23 0.42 to 3.63 0.70
* ERT denotes enzyme replacement therapy and HR hazard ratio.
† Intent-to-treat approach with ERT, age categories, and disease severity as time-dependent covariates.
‡ Values for ERT were derived after adjustment for age, sex, disease severity, and country of residence.
§ Including patients from Australia and Canada.
‡Respiratory support includes partial and full-time invasive and non-invasive respiratory support.
Figure 1 Adjusted Hazard Ratios of the Different Models
Describing the Relationship Between ERT and Survival. Model
1a: Intent-to-treat approach with enzyme replacement therapy (ERT),
age categories, and disease severity as time-dependent covariates.
Model 2a: Intent-to-treat approach with only ERT as time-dependent
covariate. Model 1b: Analysis excluding person-time after
discontinuation of treatment with ERT, age categories, and disease
severity as time-dependent covariates. Model 2b: Analysis excluding
person-time after discontinuation of treatment with only ERT as
time-dependent covariate.
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tient on ERT has a 59% smaller chance of dying than
someone not on ERT. The interpretation of this effect
over the entire follow-up period is, however, not intuitive.
Because of the time-dependent nature of the analysis it
was not possible to estimate the additional years of life
gained under ERT. However, we have made ‘ad hoc’ calcu-
lations assuming the adjusted HR can be interpreted as a
relative risk over approximately 4 years median and 8 years
maximum follow-up (from start of treatment). Using the
overall raw death rate as an estimate of the raw death rate
of the treated population (16%, 46/283), eight years of
ERT would result in 1 year of life gained.
Our estimate should be conservative as many patients
in our cohort started treatment late in their disease
course and ERT was not registered until 2006. It has
been hypothesized that starting treatment early in the
disease course results in a better clinical outcome
[9-11,13]. Indeed, all patients (with one exception) in the
ERT group who subsequently died were dependent on a
wheelchair and/or a ventilator and thus had a very ad-
vanced stage of disease when they first received ERT.
The effect of ERT on survival may therefore be greater if
treatment is initiated earlier. In addition, the positive ef-
fect of ERT observed in this analysis overall suggests that
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treatment. Further research is required to investigate the
association between disease severity and treatment effect.
Collecting sufficient data to demonstrate treatment ef-
ficacy is a challenge in rare diseases. Demonstrating
improved survival is particularly difficult in a slowly pro-
gressive disease such as adult Pompe disease. The op-
portunity to compare the natural course of Pompe
disease with the disease course following ERT highlights
the importance of our unique database. In this cohort,
the majority of patients switched from being untreated
to being treated with ERT during follow-up. Therefore,
we conducted Cox regression analyses using ERT as a
time-dependent variable, which was considered the most
suitable method because it prevents “immortal time”
bias. Immortal time bias refers to a period of follow-up
or observation time during which death cannot occur,
[21] which in our study would be the time until ERT be-
came available for the patients who survived to that time
point and received treatment afterward.
Our study was observational and did not have the sci-
entific rigor of a randomized controlled trial, which is
generally considered the most appropriate method for
comparing the effects of (alternative) treatments. How-
ever, a placebo-controlled randomized clinical trial over
as many years as in our observational study is not pos-
sible nor is it ethically acceptable to conduct; our pro-
spective follow-up study provided a valid alternative
[22]. In addition, a clinical trial requires very strict inclu-
sion and exclusion criteria and may not be representa-
tive of the entire adult Pompe patient population.
Recruitment through a patient organization could also
result in more or less severely affected patients being ex-
cluded. However, demographic and clinical characteris-
tics of our study population show that patients were
included across the entire disease spectrum and were
representative of the whole patient population. A num-
ber of confounders were adjusted for in the analysis, in-
cluding age, gender and disease severity, as well as
country of residence to capture country specific differ-
ences such as variation in approaches to care. Selection
bias was further minimized through the time dependent
nature of the analysis, as the same patient could contrib-
ute to both the untreated and treated period.
Our results were robust across the different models,
strengthening our conclusion that ERT positively influ-
ences patient survival. We used the equivalent of an
intent-to-treat approach, because this is the standard
method of analysis used to assess treatment effects in
clinical trials. This cohort included 19 patients who
stopped treatment during follow-up, and it may be per-
ceived as unfair to include their time after discontinu-
ation of ERT as “time on treatment”. An additional
analysis in which patients who discontinued treatmentwere followed only until the end of treatment provided
similar results to the intent-to-treat analyses, but with
greater statistical significance.
Conclusions
Enzyme replacement therapy with alglucosidase alfa is
currently the only approved disease-specific therapy for
Pompe disease. Although not curative, it has changed pa-
tients’ perspectives through demonstrated improvements
in muscle strength, pulmonary function, and other clinical
parameters. Our novel findings reported here show ERT
to also have a positive impact on survival of adult patients
with Pompe disease. This may be considered an important
and clinically meaningful observation, which is particu-
larly relevant with respect to the recent discussion con-
cerning the reimbursement of ultra-orphan drugs.
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